‘The knowledge is coming in, and it appears very encouraging that the US-approved vaccines do have effectiveness in opposition to this variant referred to as B1617,’ Dr Francis Collins, Director of the National Institute of Science stated
Washington: COVID-19 vaccines permitted by the United States like Pfizer, Moderna, and Johnson and Johnson have effectiveness in opposition to the B1617 variant of the virus that’s predominant in India, which is experiencing one of many worst outbreaks of the pandemic, a high American well being official stated.
The remark relies on the newest knowledge concerning the variant and the three main vaccines permitted by the United States, stated Dr Francis Collins, Director of the National Institute of Science.
“The data is coming in, and it looks very encouraging that the US-approved vaccines, the Pfizer, the Moderna, the J&J, do have effectiveness against this variant called B1617,” Collins informed the media.
“It’s a little less effective in that case than some of the others, but it looks like it ought to be good enough to make Americans protected. And that’s really a good thing to hear,” he stated in response to a query.
Early this week, the World Health Organization labeled the B1617 SARS-CoV-2 variant, which was first detected in India, as a variant of concern. The WHO stated that proof confirmed B1617 was extra transmissible.